

Biofrontera Announces Conference Call to Discuss Financial Results 2017

Leverkusen, Germany, April 19, 2018 – Biofrontera AG (Nasdaq ticker symbol: BFRA; ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended 31 December 2017 on 30 April 2018.

Conference calls for shareholders and interested investors will be held on **30 April 2018** at the following times:

10.00am CEST (4.00am EDT) conference call in German:

Dial-in number: +49-(0)69 271 340 800

Conference code: 12200651#

2.00pm CEST (8.00am EDT) conference call in English:

Dial-in number Germany: +49-(0)69 271 340 800

Dial-in number UK: +44 203 36 45 807

Dial-in number USA: +1 240 64 50 345

Dial-in number USA (New York): +1 646 66 37 901

Conference code: 51132056#

-END-

Enquiries, please contact:

+49 (0) 214 87 63 2 0
press@biofrontera.com

Biofrontera AG

Thomas Schaffer, Chief Financial Officer

IR UK: Seton Services

Toni Vallen

+44(0) 20 7729 0805

IR and PR US: The Ruth Group

IR: Tram Bui

PR: Kirsten Thomas

+1 646-536-7035

+1 508-280-6592

Biofrontera AG

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90
info@biofrontera.com | www.biofrontera.com

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)
Christoph Dünwald (CCO) | Thomas Schaffer (CFO)
Commercial register: Handelsregister Köln | **Register number:** HR B 49717 (AG)
VAT-identification number according to § 27 a UStG VAT act: DE 812374102

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

Forward Looking Statements:

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

Biofrontera AG

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90
info@biofrontera.com | www.biofrontera.com

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)
Christoph Dünwald (CCO) | Thomas Schaffer (CFO)
Commercial register: Handelsregister Köln | **Register number:** HR B 49717 (AG)
VAT-identification number according to § 27 a UStG VAT act: DE 812374102